肠道通透性
脂肪性肝炎
酒精性肝病
肠道菌群
医学
脂肪肝
肝硬化
肝病
病理生理学
脂肪变性
疾病
胃肠病学
内科学
病理
生物信息学
免疫学
生物
作者
Emidio Scarpellini,M. Forlino,M. Lupo,Carlo Rasetti,Giammarco Fava,Ludovico Abenavoli,Adriano De Santis
出处
期刊:Reviews on Recent Clinical Trials
[Bentham Science]
日期:2016-08-30
卷期号:11 (3): 213-219
被引量:26
标识
DOI:10.2174/1574887111666160810100538
摘要
The gut-liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic/toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI